Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: J Thorac Oncol. 2020 Oct 31;16(2):228–236. doi: 10.1016/j.jtho.2020.09.024

Figure 1: Performance of the 4MP in the Pittsburgh nodule cohort.

Figure 1:

A) The 4MP shows an AUC of 0.76 (95% CI 0.69–0.82). Three of the markers performed moderately well, including pro-SFTPB (B) with an area under the curve (AUC) of the receiver operative characteristic (ROC) of 0.69 (95% CI 0.62–0.77), CEA (C) at 0.70 (95% CI 0.63–0.77), and CYFRA21–1 (D) at 0.72 (95% CI 0.65–0.80). CA125 (E) did not show statistical significance with an AUC of 0.57 (95% CI 0.49–0.65, Table 1E).